跳转至内容
Merck

H-102

Supelco

4-羟基杜洛西汀-β-D-葡萄糖醛酸苷 溶液

100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H27NO8S
分子量:
489.54
MDL號碼:
分類程式碼代碼:
41116107

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

100 μg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

−20°C

一般說明

4-Hydroxyduloxetine glucuronide is a metabolite of duloxetine. Duloxetine, marketed in the US under the trade name Cymbalta® is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder and to alleviate pain associated with diabetic neuropathy, fibromyalgia, and osteoarthritis. This Certified Spiking Solution® is applicable for use in applications such as clinical toxicology, urine drug testing, and forensic analysis by LC-MS/MS or GC/MS.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Cymbalta is a registered trademark of Eli Lilly and Co.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M A Smit et al.
Oncogene, 30(35), 3735-3744 (2011-04-12)
Anoikis (detachment-induced apoptosis) prevents the survival of cells at inappropriate sites of the body and can therefore act as a barrier to metastasis. In a function-based genome-wide screen, we have previously identified the neurotrophic tyrosine kinase receptor TrkB as a
Deyin Xing et al.
Cancer research, 69(21), 8231-8235 (2009-10-22)
Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate. Currently, there is no effective treatment for ULMS. Infrequent occurrences of human ULMS hamper the understanding of the initiation and progression of the disease, thereby limiting the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门